Literature DB >> 18418493

Canadian Consensus Recommendations for the Optimal Use of Enfuvirtide in HIV/AIDS Patients.

Anita Rachlis1, Jonathan Angel, Marianne Harris, Richard Lalonde, Fiona Smaill, Cecile Tremblay, Chris Tsoukas, Sharon Walmsley.   

Abstract

BACKGROUND AND OBJECTIVES: An eight-member group consisting of Canadian infectious disease and immunology specialists and a family physician with significant experience in HIV management was convened to update existing recommendations, specifically intended for use by Canadian HIV-treating physicians, on the appropriate use of enfuvirtide in HIV/AIDS patients with resistance to other antiretroviral drugs.
METHODS: Evidence from the literature and expert opinions of the group members formed the basis of the guidelines. Comments on the draft guidelines were obtained from other physicians across Canada with HIV expertise. The final guidelines represent the group's consensus agreement. RESULTS AND
CONCLUSIONS: The recommendations were developed to guide physicians in optimal practices in patient selection for enfuvirtide treatment and subsequent patient management. The issues considered include positive predictors of response to enfuvirtide, stage of disease, optimization of the background regimen, early indicators of enfuvirtide response, and patient education and support.

Entities:  

Keywords:  AIDS; HIV; Recommendations; Treatment

Year:  2006        PMID: 18418493      PMCID: PMC2095068          DOI: 10.1155/2006/402409

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  36 in total

1.  A compromise strategy for patients with multiple drug failure.

Authors:  J S Montaner; M Harris; R Harrigan; R Hogg; E Wood
Journal:  AIDS       Date:  2001-12-07       Impact factor: 4.177

2.  Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide.

Authors:  Sharon Walmsley; Keith Henry; Christine Katlama; Mark Nelson; Antonella Castagna; Jacques Reynes; Bonaventura Clotet; James Hui; Miklos Salgo; Ralph DeMasi; John Delehanty
Journal:  J Infect Dis       Date:  2003-12-05       Impact factor: 5.226

Review 3.  Resistance to enfuvirtide, the first HIV fusion inhibitor.

Authors:  Michael L Greenberg; Nick Cammack
Journal:  J Antimicrob Chemother       Date:  2004-07-01       Impact factor: 5.790

4.  Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report.

Authors:  Martin Markowitz; Hiroshi Mohri; Saurabh Mehandru; Anita Shet; Leslie Berry; Roopa Kalyanaraman; Alexandria Kim; Chris Chung; Patrick Jean-Pierre; Amir Horowitz; Melissa La Mar; Terri Wrin; Neil Parkin; Michael Poles; Christos Petropoulos; Michael Mullen; Daniel Boden; David D Ho
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

5.  CD4(+) cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy.

Authors:  Mona R Loutfy; Sharon L Walmsley; Christopher M Mullin; George Perez; James D Neaton
Journal:  J Infect Dis       Date:  2005-09-09       Impact factor: 5.226

6.  HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach.

Authors:  P Richard Harrigan; Brian Wynhoven; Zabrina L Brumme; Chanson J Brumme; Beheroze Sattha; Jennifer C Major; Rafael de la Rosa; Julio S G Montaner
Journal:  J Infect Dis       Date:  2005-03-16       Impact factor: 5.226

7.  Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).

Authors:  Jing Lu; Prakash Sista; Françoise Giguel; Michael Greenberg; Daniel R Kuritzkes
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients.

Authors:  Xiaoping Zhang; Jacob P Lalezari; Andrew D Badley; Albert Dorr; Stanley J Kolis; Tosca Kinchelow; Indravadan H Patel
Journal:  Clin Pharmacol Ther       Date:  2004-06       Impact factor: 6.875

Review 9.  Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations.

Authors:  Bonaventura Clotet; François Raffi; David Cooper; Jean-François Delfraissy; Adriano Lazzarin; Graeme Moyle; Jürgen Rockstroh; Vincent Soriano; Jonathan Schapiro
Journal:  AIDS       Date:  2004-05-21       Impact factor: 4.177

10.  Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children.

Authors:  Joseph A Church; Michael Hughes; Jie Chen; Paul Palumbo; Lynne M Mofenson; Patricia Delora; Elizabeth Smith; Andrew Wiznia; Elizabeth Hawkins; Prakash Sista; Coleen K Cunningham
Journal:  Pediatr Infect Dis J       Date:  2004-08       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.